Seasonal allergic rhinitis (SAR) is a chronic inflammatory condition primarily mediated by type 2 immune responses, typically triggered by specific pollens. Stapokibart is a humanized monoclonal antibody anti-interleukin-4 receptor alpha subunit, thereby blocking IL-4 and IL-13 signaling pathways. Clinical studies of stapokibart in healthy adults and SAR patients revealed a favorable safety profile and significant clinical efficacy. Stapokibart has been approved for treating adults with atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and SAR in China. This article reviews the mechanism of action, pharmacology, and available clinical trial data regarding the efficacy and safety of stapokibart in SAR.
基金：
National Natural Science Foundation of China [82371115]; Beijing Hospitals Authority Clinical Medicine Development of special funding [ZLRK202303]
第一作者机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China[2]Beijing Inst Otolaryngol, Beijing Lab Allerg Dis, Beijing, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China[2]Beijing Inst Otolaryngol, Beijing Lab Allerg Dis, Beijing, Peoples R China[3]Capital Med Univ, Beijing Tongren Hosp, Dept Allergy, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wang Menglin,Li Jingyun,Zhang Luo,et al.Evaluating stapokibart in the treatment of seasonal allergic rhinitis[J].IMMUNOTHERAPY.2025,17(12):851-860.doi:10.1080/1750743X.2025.2554562.
APA：
Wang, Menglin,Li, Jingyun,Zhang, Luo&Zhang, Yuan.(2025).Evaluating stapokibart in the treatment of seasonal allergic rhinitis.IMMUNOTHERAPY,17,(12)
MLA：
Wang, Menglin,et al."Evaluating stapokibart in the treatment of seasonal allergic rhinitis".IMMUNOTHERAPY 17..12(2025):851-860
